Directorate Change

RNS Number : 6611G

Scancell Holdings Plc

09 May 2014

 



9 May 2014

Scancell Holdings Plc

('Scancell' or the "Company")

Directorate Change

Scancell Holdings Plc (AIM:SCLP) announces that Mr Peter Allen will be stepping down as a non-executive Director as of today's date.  The Board would like to thank Peter for his work during his time on the Board.

For Further Information:

Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc Scancell Holdings Plc	+ 44 (0) 20 7831 3113
Camilla Hume/Stephen Keys	Cenkos Securities plc	+ 44 (0) 20 7397 8900
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.  Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated  in a Phase 1/2 clinical trial.  Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend  

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

BOAUWAWRSAAVRAR